GLP-1-based therapies for diabetes, obesity and beyond

Coverage of GLP-1 weight-loss drugs is growing among the largest employers (5000+ workers), now at 43%

But the drugs are deemed generally safe by the FDA, and parents whose kids are taking them, and the doctors prescribing them, say the benefit of preventing or slowing the progression of obesity-related chronic conditions, such as type 2 diabetes and heart disease that worsen with age, outweighs these risks

Malhotra has submitted a grant proposal to the National Institutes of Health to explore this issue

Some patients find 200 to 400 mg at bedtime helps with both bowel regularity and sleep

19 This research culminated in the development of dapagliflozin, canagliflozin, and empagliflozin, which were approved by the FDA between 2013 and 2014 for the treatment of T2D

Semaglutide and liraglutide have been used for years with reassuring safety profiles

GLP-1s Offer New Hope When Treatment Options Are Limited A growing share of providers are prescribing GLP‑1 therapies to manage multiple conditions, a trend particularly evident in comorbidities where few therapeutic options exist

Protein requirements become critical Both menopause and GLP-1-induced weight loss put muscle mass at risk

Research shows that fatty liver disease is associated with a 64% increased risk of heart attack or stroke

Patients may find themselves ruminating about health concerns, weight loss progress, or other life stressors

However, it also has a positive effect on obesity

Understanding Your $50 Copay Does it count toward my Part D deductible